Abbott
Income Statement Highlights (What's this?)
Avg. Est. | Q2 2005 | Q2 2004 | % Change | |
---|---|---|---|---|
Sales | $5,280,000 | $5,523,800 | $4,703,049 | +17.5% |
Net Profit | -- | $877,052 | $634,258 | +38.3% |
EPS | $0.57 | $0.56 | $0.40 | +40.0% |
Margin Checkup (What's this?)
Q2 2005 | Q2 2004 | % Change | |
---|---|---|---|
Gross Margin | 52.35% | 56.01% | -3.66% |
Op. Margin | 19.82% | 16.93% | +2.89% |
Net Margin | 15.88% | 13.49% | +2.39% |
Balance Sheet Highlights (What's this?)
No balance sheet provided.
Related Companies:
-
Pfizer
(NYSE:PFE) -
Merck
(NYSE:MRK) -
Eli Lilly
(NYSE:LLY) -
Bristol-Myers Squibb
(NYSE:BMY) -
Schering-Plough
(NYSE:SGP)
Related Foolishness:
If you would like our Foolish analysis of similar companies, why not take a 30-day free trial to Motley Fool Rule Breakers?
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean.
At the time of publication, John Reeves did not own shares in any of the companies mentioned. Fool rules are here.